Whole genome CRISPRi screening identifies druggable vulnerabilities in an isoniazid resistant strain of Mycobacterium ...
Rutgers Health research has uncovered why a relatively new antibiotic for tuberculosis (TB) works against multidrug-resistant strains, potentially inspiring improved treatments and drug development ...
Isoniazid is a first-line medicine for tuberculosis (TB) treatment. It is a prodrug activated by the mycobacterial catalase-peroxidase enzyme KatG. However, the development of isoniazid resistance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback